Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial

M. Ripa, M. Pogliaghi, S. Chiappetta, L. Galli, S. Pensieroso, M. Cavarelli, G. Scarlatti, S. De Biasi, A. Cossarizza, D. De Battista, M. Malnati, A. Lazzarin, S. Nozza, G. Tambussi

Research output: Contribution to journalArticle


We evaluated the dynamics of innate and adaptive immunity in patients treated with combined antiretroviral therapy (cART) during primary human immunodeficiency virus infection (PHI), enrolled in a prospective randomized trial (MAIN, EUDRACT 2008-007004-29). After 48 weeks of cART, we documented a reduction in activated B cells and CD8(+) T cells. Natural killer cell and dendritic cell frequencies were measured and a decrease in CD16(+) CD56(dim) with a reciprocal rise in CD56(high) natural killer cells and an increase in myeloid and plasmacytoid dendritic cells were recorded. In conclusion, 48 weeks of cART during PHI showed significant benefits for both innate and adaptive immunity.

Original languageEnglish
JournalClinical Microbiology and Infection
Issue number9
Publication statusPublished - Sep 1 2015



  • B cells
  • dendritic cells
  • immune activation
  • natural killer cells
  • primary human immunodeficiency virus type 1 infection

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this